Clinical Trial Update: A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease [Phase 3]

View source ↗

Summary

A Phase 3 open-label trial comparing PARCOPA (carbidopa/levodopa orally disintegrating tablets) with conventional carbidopa/levodopa tablets in Parkinson's dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Carbidopa/Levodopa tablets (carbidopa/levodopa)
• Parcopa (carbidopa-levodopa)

Snippet

Sponsor: UCB Pharma | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED